By bringing innovative therapies to the patients, Venture Capitals aim to increase the value of their companies in the most efficient and fastest possible way.
As any failure of a new drug candidate can lead to significant losses, at NUVISAN we understand the interest of derisking the compound and optionally sharing the risk with you.
With a proven track-record of customer satisfaction, NUVISAN can partner with you to increase the value of your companies from today!
NUVISAN can support building companies from very early stages both as Specialist consultants for R&D and as Executive Partner for Drug Discovery and Development. Our more than 400 scientists, with decades of experience in drug development, are able to perform whole integrated programs from target ID to clinical trials.
The Innovation Campus Berlin – Germany- has been running for many years to the benefit of a major pharmaceutical player. Now ICB is available to the industry for the first time from Target Identification to Candidate Selection, through to hit identification, hit-to-lead, Lead optimization, DMPK profiling and IND enabling studies under GLP where appropriate.
In addition, as Scientific consultants, we will:
NUVISAN can support Venture Capitals already during the Due Diligence stage, as a specialist consulting partner. We can:
Contact email@example.com to learn how to start increasing the value of your company with NUVISAN.